3-Butyryloxy-phenol | 114398-12-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 3-Butyryloxy-phenol
• 英文别名: (3-Hydroxyphenyl) butanoate
• CAS: 114398-12-8
• 化学式: C₁₀H₁₂O₃
• 分子量: 180.203
• InChiKey: JXZDAFPSAJTZRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  丁酸酐 、 间苯二酚 在 sodium hydroxide 作用下， 生成 3-Butyryloxy-phenol
  参考文献：
  名称：

  Israelstam; Simpson, Journal of the South African Chemical Institute, 1956, vol. 9, p. 92

  摘要：

  DOI：

文献信息

• [EN] A NOVEL PROCESS FOR THE PREPARATION OF CILAZAPRIL<br/>[FR] PROCEDE D'ELABORATION DE CILAZAPRIL
  申请人：HETERO DRUGS LTD

  公开号：WO2005003134A1

  公开（公告）日：2005-01-13

  Cilazapril is prepared in good yield using ethyl R-2-(nitro or halo substituted benzene sulfonyloxy)-4-phenyl butyrate. Thus, (1S,9S)-t-butyl octahydro-10-oxo-9-amino-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate is reacted with ethyl R-2-(4-nitro benzene sulfonyloxy)-4-phenyl butyrate in the presence of N-methyl morpholine followed by treatment with hydrogen chloride to give cilazapril.

  Cilazapril是使用乙酰R-2-(硝基或卤代苯磺酰氧基)-4-苯基丁酸乙酯高产制备的。因此，(1S,9S)-叔丁基八氢-10-氧代-9-氨基-6H-吡啶并[1,2-a][1,2]二氮杂环-1-羧酸乙酯与乙酰R-2-(4-硝基苯磺酰氧基)-4-苯基丁酸乙酯在N-甲基吗啡醇的存在下反应，随后经氯化氢处理得到Cilazapril。
• Antihypertensive dihydropyridine derivatives
  申请人：LABORATOIRES SYNTEX S.A.

  公开号：EP0249245A2

  公开（公告）日：1987-12-16

  Compounds of formula 1 as their racemic mixtures or optical isomers are calcium entry antagonists useful for treating hypertension, congestive heart failure, angina, and vasospastic disorders: wherein n is an integer from 1 to 4; R1 and R2 are lower alkyl; R3 is lower alkyl or alkoxyalkyl; A is alkylene of two to eight carbon atoms; X1 and X2 are each independently -N02, -CF3, CH30-, -CN, -H, lower alkyl or halo; Y is -O-, -S-, -S(O)-, or -S(O)2-; and R is H or R' wherein R' is lower alkyl, cycloalkyl, alkoxyalkyl, cycloalkyloxy-alkyl, alkoxycycloalkyl, acyl, or saturated or unsaturated 5-or 6-membered heterocyclyl optionally substituted with lower alkyl or alkoxy, wherein the heteroatom is one oxygen atom.

  式 1 的化合物作为其外消旋混合物或光学异构体是钙离子进入拮抗剂，可用于治疗高血压、充血性心力衰竭、心绞痛和血管痉挛性疾病： 其中 n 是 1 到 4 的整数；R1 和 R2 是低级烷基；R3 是低级烷基或烷氧基烷基；A 是 2 到 8 个碳原子的亚烷基；X1 和 X2 各自独立地是-N02、-CF3、CH30-、-CN、-H、低级烷基或卤代；Y 是-O-、-S-、-S(O)- 或-S(O)2-；R是H或R'，其中R'是低级烷基、环烷基、烷氧基烷基、环烷氧基烷基、烷氧基环烷基、酰基或饱和或不饱和的5或6元杂环烷基，可任选被低级烷基或烷氧基取代，其中杂原子是一个氧原子。
• Process for making and isolating (R)-2-hydroxy 4-phenylbutyric acid and esters
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0280285A2

  公开（公告）日：1988-08-31

  Disclosed herein is a novel compound, (L)-menthyl 2-oxo-4-phenylbutyrate, and an improved process for making and isolating a substantially pure compound of the structural formula: wherein Y is hydrogen or (L)-menthyl the improvement which comprises: a) stereoselectively reducing (L)-menthyl 2-oxo-4-­phenylbutyrate by contacting said compound with with S-Alpine borane, b) stereoselectively isolating (L)-menthyl-(R)-2-­hydroxy-4-phenylbutyrate by crystallization, and optionally hydrolyzing the so obtained ester; and further comprises optionally esterifying the so obtained acid by contacting said acid with a C₁-C₆ alkanol in the presence of acid.

  本文公开了一种新型化合物(L)-2-氧代-4-苯基丁酸孟酯，以及一种用于制造和分离结构式为： 其中 Y 为氢或(L)-孟基的基本纯化合物的改进工艺，该改进工艺包括：a) 通过将所述化合物与 S-Alpine 硼烷接触，立体选择性地还原(L)-2-氧代-4-苯基丁酸孟酯；b) 通过结晶立体选择性地分离(L)-孟基-(R)-2-羟基-4-苯基丁酸孟酯，并选择性地水解所获得的酯；还包括在酸存在下，通过将所述酸与 C₁-C₆ 烷醇接触，选择性地酯化所获得的酸。
• Process for racemization of optically active 4-phenylbutanoic acid esters
  申请人：KURARAY CO., LTD.

  公开号：EP0421472A1

  公开（公告）日：1991-04-10

  A process for the racemization of optically active 4-phenylbutanoic acid esters which comprises treating optically active 4-phenylbutanoic acid esters of the general formula (I) wherein R¹ represents a hydroxy group, a hydroxy group protected by a vinyl ether, or a lower acyloxy group and R² repesents a lower alkyl group with a base selected from the group consisting of alkali metal alcoholates, alkali metal hydrides, and alkali metal amides is provided.

  一种使光学活性 4-苯基丁酸酯消旋化的工艺，包括用通式(I)处理光学活性 4-苯基丁酸酯 其中 R¹ 代表羟基、受乙烯基醚保护的羟基或低级酰氧基，R² 代表低级烷基，其碱选自碱金属醇酸盐、碱金属氢化物和碱金属酰胺组成的组。
• Enantiomer separation by transesterification
  申请人：SEPRACOR, INC.

  公开号：EP0461043A2

  公开（公告）日：1991-12-11

  Disclosed is a process for resolving enantiomeric mixtures of 2-substituted propanoic acids and related compounds by first derivatizing the compounds to produce water soluble ester forms of the acids, and using the ester forms in an enantiomerically selective enzyme catalyzed reaction. The water soluble substrates are disposed in an aqueous solution of a water soluble donor alcohol in the presence of a hydrolase enzyme and produce by transesterification a product ester rich in one of the two enantiomers having reduced water solubility. Separation of the enantiomers thereafter may be conducted using various conventional means. The process is versatile and efficient because it can be conducted in aqueous solution to produce an easily separated product which inherently is a relatively poor substrate for hydrolase enzyme catalyzed hydrolysis.

  本发明公开了一种用于解析 2-取代丙酸及相关化合物对映体混合物的工艺，首先对这些化合物进行衍生处理，生成这些酸的水溶性酯形式，然后在对映体选择性酶催化反应中使用这些酯形式。在水解酶存在的情况下，将水溶性底物置于水溶性供体醇的水溶液中，通过酯交换反应生成富含两种对映体之一的酯，其水溶性降低。此后，对映体的分离可通过各种常规方法进行。该工艺用途广泛，效率高，因为它可以在水溶液中进行，生产出易于分离的产品，而该产品本身是水解酶催化水解的相对较差的底物。